Limits...
Biomarkers of cancer angioprevention for clinical studies.

Albini A, Bertolini F, Bassani B, Bruno A, Gallo C, Caraffi SG, Maramotti S, Noonan DM - Ecancermedicalscience (2015)

Bottom Line: Prevention approaches range from avoiding tobacco exposure to dietary strategies to active pharmacological approaches in higher risk groups.Angioprevention i.e. preventing cancer angiogenesis is a key concept that we introduced; yet one of the major current challenges for anti-angiogenesis in therapy and prevention is finding the right biomarkers.Here we discuss the importance of angioprevention and the potential use of VEGF, PlGF, CD31, Ang and Tie, circulating vascular cell precursors, and microRNA as potential biomarkers.

View Article: PubMed Central - PubMed

Affiliation: Laboratory of Translational Oncology, Department of Research and Statistics, IRCCS Arcispedale Santa Maria Nuova, Reggio Emilia 42123, Italy ; These authors share equal contribution.

ABSTRACT
With the great advances made in the treatment and prevention of infectious diseases over the last century, chronic degenerative diseases-cardiovascular, cerebrovascular, and cancer-represent the major causes of death in the developed world. Although massive efforts and investments have been made in cancer therapy, the progress made towards reducing mortality has been more successful for cardiovascular disease than for tumours. This can be attributable largely to an active prevention approach implemented for cardiovascular disease. Cardiologists treat their patients before the overt disease becomes life threatening, performing early interventions in phenotypically healthy patients, by using several markers that predict risk. If the concept of prevention could be applied to cancer in a more extensive way, a significant number of tumours could be avoided through preventive measures. Prevention approaches range from avoiding tobacco exposure to dietary strategies to active pharmacological approaches in higher risk groups. Host targets rather than the tumour cells themselves are attractive for chemoprevention, in particular endothelial and immune cells. Angioprevention i.e. preventing cancer angiogenesis is a key concept that we introduced; yet one of the major current challenges for anti-angiogenesis in therapy and prevention is finding the right biomarkers. Here we discuss the importance of angioprevention and the potential use of VEGF, PlGF, CD31, Ang and Tie, circulating vascular cell precursors, and microRNA as potential biomarkers.

No MeSH data available.


Related in: MedlinePlus

Selected biomarkers of angiogenesis. Many laboratories look for biomarkers that can be traced in the peripheral blood, since they would be relatively non-invasive and convenient for keeping track of patient responses to antiangiogenic treatments. These biomarkers include soluble factors secreted by both tumour and stromal cells, such as VEGF or PlGF, or microenvironment-derived proteins such as SDF1 or the Ang1/Ang2/Tie2 ligand-receptor system. Novel, promising strategies involve the detection of circulating cells such as CECs or CEPs, although specific surface antigens for their unequivocal discrimination still requires validation [37, 38].
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4664506&req=5

figure3: Selected biomarkers of angiogenesis. Many laboratories look for biomarkers that can be traced in the peripheral blood, since they would be relatively non-invasive and convenient for keeping track of patient responses to antiangiogenic treatments. These biomarkers include soluble factors secreted by both tumour and stromal cells, such as VEGF or PlGF, or microenvironment-derived proteins such as SDF1 or the Ang1/Ang2/Tie2 ligand-receptor system. Novel, promising strategies involve the detection of circulating cells such as CECs or CEPs, although specific surface antigens for their unequivocal discrimination still requires validation [37, 38].

Mentions: Numerous laboratories across the globe are now looking into other types of markers for response to therapy, in particular anti-angiogenic therapy, which will also shed light on their angiopreventive effects. Candidate predictive biomarkers include germline single nucleotide polymorphisms (SNPs) of angiogenesis-related growth factors and receptors such as VEGF, VEGFR, PlGF [43, 44], and expression of microRNAs and other non-coding RNAs (Figure 3). Interestingly, recent studies suggest that several phytocompounds are able to modulate the expression of microRNAs [45–47]. The effects that phytochemicals exert through miR modulation are likely to contribute to the overall performance of these molecules.


Biomarkers of cancer angioprevention for clinical studies.

Albini A, Bertolini F, Bassani B, Bruno A, Gallo C, Caraffi SG, Maramotti S, Noonan DM - Ecancermedicalscience (2015)

Selected biomarkers of angiogenesis. Many laboratories look for biomarkers that can be traced in the peripheral blood, since they would be relatively non-invasive and convenient for keeping track of patient responses to antiangiogenic treatments. These biomarkers include soluble factors secreted by both tumour and stromal cells, such as VEGF or PlGF, or microenvironment-derived proteins such as SDF1 or the Ang1/Ang2/Tie2 ligand-receptor system. Novel, promising strategies involve the detection of circulating cells such as CECs or CEPs, although specific surface antigens for their unequivocal discrimination still requires validation [37, 38].
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4664506&req=5

figure3: Selected biomarkers of angiogenesis. Many laboratories look for biomarkers that can be traced in the peripheral blood, since they would be relatively non-invasive and convenient for keeping track of patient responses to antiangiogenic treatments. These biomarkers include soluble factors secreted by both tumour and stromal cells, such as VEGF or PlGF, or microenvironment-derived proteins such as SDF1 or the Ang1/Ang2/Tie2 ligand-receptor system. Novel, promising strategies involve the detection of circulating cells such as CECs or CEPs, although specific surface antigens for their unequivocal discrimination still requires validation [37, 38].
Mentions: Numerous laboratories across the globe are now looking into other types of markers for response to therapy, in particular anti-angiogenic therapy, which will also shed light on their angiopreventive effects. Candidate predictive biomarkers include germline single nucleotide polymorphisms (SNPs) of angiogenesis-related growth factors and receptors such as VEGF, VEGFR, PlGF [43, 44], and expression of microRNAs and other non-coding RNAs (Figure 3). Interestingly, recent studies suggest that several phytocompounds are able to modulate the expression of microRNAs [45–47]. The effects that phytochemicals exert through miR modulation are likely to contribute to the overall performance of these molecules.

Bottom Line: Prevention approaches range from avoiding tobacco exposure to dietary strategies to active pharmacological approaches in higher risk groups.Angioprevention i.e. preventing cancer angiogenesis is a key concept that we introduced; yet one of the major current challenges for anti-angiogenesis in therapy and prevention is finding the right biomarkers.Here we discuss the importance of angioprevention and the potential use of VEGF, PlGF, CD31, Ang and Tie, circulating vascular cell precursors, and microRNA as potential biomarkers.

View Article: PubMed Central - PubMed

Affiliation: Laboratory of Translational Oncology, Department of Research and Statistics, IRCCS Arcispedale Santa Maria Nuova, Reggio Emilia 42123, Italy ; These authors share equal contribution.

ABSTRACT
With the great advances made in the treatment and prevention of infectious diseases over the last century, chronic degenerative diseases-cardiovascular, cerebrovascular, and cancer-represent the major causes of death in the developed world. Although massive efforts and investments have been made in cancer therapy, the progress made towards reducing mortality has been more successful for cardiovascular disease than for tumours. This can be attributable largely to an active prevention approach implemented for cardiovascular disease. Cardiologists treat their patients before the overt disease becomes life threatening, performing early interventions in phenotypically healthy patients, by using several markers that predict risk. If the concept of prevention could be applied to cancer in a more extensive way, a significant number of tumours could be avoided through preventive measures. Prevention approaches range from avoiding tobacco exposure to dietary strategies to active pharmacological approaches in higher risk groups. Host targets rather than the tumour cells themselves are attractive for chemoprevention, in particular endothelial and immune cells. Angioprevention i.e. preventing cancer angiogenesis is a key concept that we introduced; yet one of the major current challenges for anti-angiogenesis in therapy and prevention is finding the right biomarkers. Here we discuss the importance of angioprevention and the potential use of VEGF, PlGF, CD31, Ang and Tie, circulating vascular cell precursors, and microRNA as potential biomarkers.

No MeSH data available.


Related in: MedlinePlus